The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Endo International plc (NASDAQ:ENDP) between November 30, 2012 and July 6, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Bier v. Endo International plc, et al. (Case No. 2:17-cv-03711-TJS) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information go to: http://www.zlk.com/pslra-sbm/endo-international-plc?wire=2 or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company's branded pharmaceutical Opana ER. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market. If you suffered a loss in Endo you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.